BB&T Corp cut its holdings in Merck & Co., Inc. (NYSE:MRK) by 2.1% in the 4th quarter, HoldingsChannel reports. The fund owned 561,378 shares of the company’s stock after selling 11,861 shares during the period. BB&T Corp’s holdings in Merck & Co., Inc. were worth $31,588,000 at the end of the most recent quarter.
Other hedge funds have also bought and sold shares of the company. Pax World Management LLC increased its position in Merck & Co., Inc. by 9.6% in the 2nd quarter. Pax World Management LLC now owns 333,794 shares of the company’s stock valued at $21,393,000 after buying an additional 29,135 shares in the last quarter. Apriem Advisors increased its position in Merck & Co., Inc. by 0.7% in the 2nd quarter. Apriem Advisors now owns 8,146 shares of the company’s stock valued at $522,000 after buying an additional 60 shares in the last quarter. Mosaic Family Wealth LLC increased its position in Merck & Co., Inc. by 3.0% in the 2nd quarter. Mosaic Family Wealth LLC now owns 3,381 shares of the company’s stock valued at $217,000 after buying an additional 97 shares in the last quarter. Tocqueville Asset Management L.P. increased its position in Merck & Co., Inc. by 1.2% in the 2nd quarter. Tocqueville Asset Management L.P. now owns 1,029,256 shares of the company’s stock valued at $65,965,000 after buying an additional 12,471 shares in the last quarter. Finally, RiverPoint Capital Management LLC increased its position in Merck & Co., Inc. by 2.6% in the 2nd quarter. RiverPoint Capital Management LLC now owns 362,673 shares of the company’s stock valued at $23,244,000 after buying an additional 9,269 shares in the last quarter. 72.97% of the stock is owned by hedge funds and other institutional investors.
In other news, Director Wendell P. Weeks sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $53.57, for a total value of $267,850.00. Following the transaction, the director now owns 5,100 shares in the company, valued at approximately $273,207. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Weir Mirian M. Graddick sold 60,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $61.63, for a total value of $3,697,800.00. Following the completion of the transaction, the insider now owns 101,484 shares in the company, valued at approximately $6,254,458.92. The disclosure for this sale can be found here. Insiders sold a total of 82,500 shares of company stock worth $5,026,025 in the last 90 days. Company insiders own 0.25% of the company’s stock.
Merck & Co., Inc. (NYSE MRK) opened at $55.14 on Friday. Merck & Co., Inc. has a 12 month low of $53.12 and a 12 month high of $66.41. The firm has a market capitalization of $148,670.00, a P/E ratio of 30.30, a PEG ratio of 2.26 and a beta of 0.81. The company has a quick ratio of 1.06, a current ratio of 1.33 and a debt-to-equity ratio of 0.62.
Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Friday, February 2nd. The company reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.94 by $0.04. Merck & Co., Inc. had a return on equity of 28.61% and a net margin of 6.40%. The firm had revenue of $10.43 billion for the quarter, compared to the consensus estimate of $10.48 billion. During the same quarter in the previous year, the business earned $0.89 EPS. The company’s revenue was up 3.1% compared to the same quarter last year. research analysts forecast that Merck & Co., Inc. will post 4.16 earnings per share for the current fiscal year.
Merck & Co., Inc. declared that its Board of Directors has authorized a share repurchase program on Tuesday, November 28th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the company to reacquire shares of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.
The firm also recently announced a quarterly dividend, which will be paid on Friday, April 6th. Stockholders of record on Thursday, March 15th will be paid a $0.48 dividend. The ex-dividend date is Wednesday, March 14th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 3.48%. Merck & Co., Inc.’s payout ratio is presently 105.49%.
WARNING: “Merck & Co., Inc. (MRK) Shares Sold by BB&T Corp” was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3254699/merck-co-inc-mrk-shares-sold-by-bbt-corp.html.
Merck & Co., Inc. Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.